Back to top
more

Dare Bioscience (DARE)

(Delayed Data from NSDQ)

$2.42 USD

2.42
112,259

+0.02 (0.83%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $2.42 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dare Bioscience (DARE) delivered earnings and revenue surprises of 20.63% and 95.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Acadia Healthcare (ACHC) Beats Q1 Earnings Estimates

by Zacks Equity Research

Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 14.29% and 0%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -125% and 5.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Dare Bioscience (DARE) delivered earnings and revenue surprises of 3.03% and 101.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of -13.33% and 1.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 13.99% and 2.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dare Bioscience (DARE) delivered earnings and revenue surprises of 8.33% and 98.64%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Immunome (IMNM) delivered earnings and revenue surprises of -30% and 19.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Absci Corporation (ABSI) delivered earnings and revenue surprises of -26.32% and 4.01%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Lags Q3 Earnings Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -14.81% and 0.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Dare Bioscience (DARE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

Zacks Equity Research

HOLX Launches BustTheMyth Campaign for Breast Health Awareness

by Zacks Equity Research

Hologic enters Breast Cancer Awareness Month with the launch of the BustTheMyth campaign. This campaign is aimed at busting myths regarding breast health.

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates

by Zacks Equity Research

Dare Bioscience (DARE) delivered earnings and revenue surprises of 366.67% and 96.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 10% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 28.57% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis

by Zacks Equity Research

Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of -63.64% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy

by Zacks Equity Research

Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.